NEW YORK, July 8, 2024 (GLOBE NEWSWIRE) –
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court by 3 September 2024 at the latest.
SO WHAT: If you purchased Bolt securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Bolt class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information about the class action lawsuit. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court by 3 September 2024 at the latestA lead plaintiff is a representative party directing the litigation on behalf of other class members.
WHY ROSEN LAW: We encourage investors to select qualified attorneys with a track record of success in leadership roles. Often, the firms that file lawsuits do not have comparable experience, resources, or significant peer recognition. Choose your attorneys wisely. The Rosen Law Firm represents investors around the world and focuses on securities class actions and shareholder derivatives litigation. The Rosen Law Firm has achieved the highest settlement in a securities class action against a Chinese company. The Rosen Law Firm was ranked No. 1 in 2017 by ISS Securities Class Action Services for number of securities class action settlements. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BDC-1001, Bolt’s immune-stimulating antibody conjugate (“ISAC”), which targets a tumor antigen called human epidermal growth factor receptor 2 (“HER2”), which is commonly found in cancers such as breast and esophageal cancer, was less effective than the company had represented to investors and was unlikely to meet pre-established success criteria; (2) accordingly, defendants overstated the clinical and/or commercial prospects of Bolt’s product pipeline, which the company relies on primarily to sustain its business model; (3) all of which placed the company at increased risk of disruptive leadership changes and significant reductions in personnel; and (4) as a result, the company’s public statements were materially false and misleading at all relevant times. When the true details became available to the market, the lawsuit alleges that investors suffered damages.
To join the Bolt class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information about the class action lawsuit.
No class action has been certified. Until a class action is certified, you will not be represented by counsel unless you hire one. You may select counsel of your choice. You may also remain as an absent class member and take no action at this time. An investor’s ability to share in any potential future recovery is not dependent on serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney advertising. Past results do not guarantee a similar result.
Contact information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Law Firm of Rosen, PA
275 Madison Avenue, 40th floor
New York, NY 10016
Phone: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
